NCT06355934Recruiting
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
OverTTuRe: An Observational Multi-Country Study Collecting Real-World Secondary Data on the Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
Source: ClinicalTrials.gov · Last updated 9 Sept 2026
Brief summary (registry, in English)
The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics, treatment patterns and selected clinical, economic, and humanistic outcomes (for example Health Related Quality of Life (HRQoL), Neuropathy impairment score, activities of daily living (ADL) assessments) in patients with ATTR amyloidosis, and to better understand how the disease is presented.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 52121 (estimated)
- First submitted
- 12 Feb 2024
- Start date
- 21 Aug 2023
- Primary completion date
- 2 Nov 2026
- Lead sponsor
- AstraZeneca
- Diseases
- Amyloidosis
- NCT number
- NCT06355934
What you commit to
- Study type: Observational
- Planned participants: 52121
- From 21 Aug 2023 to the primary completion date, 2 Nov 2026
- 29 sites in 11 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- At least one claim/procedure code for stem cell transplant or at least two claims/procedure codes for chemotherapy and autoimmune disease drugs which may represent AL (primary) or AA (secondary) amyloidosis treatments
Other
- Evidence of primary (AL) and secondary (AA) amyloidosis AND/OR
Who the study is looking for
- Patients aged \>18 years at study index date AND
- A reported diagnosis code for amyloidosis OR
- A claim for ATTR-specific treatment OR
- A positive biopsy for amyloidosis and positive immunostaining result of biopsy for ATTR
Sex: All · Does not accept healthy volunteers
Sites (29)
Sites in registry order. Pick your city on the disease page to sort them by distance.
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.